Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane conductance regulator modulator, which has shown efficacy in CF patients (≥6 years) with ≥1 Phe508del mutation and a minimal function mutation. In October 2019, ETI became available on compassionate use basis for Dutch CF...

Descripción completa

Detalles Bibliográficos
Autores principales: Kos, Renate, Neerincx, Anne H., Fenn, Dominic W., Brinkman, Paul, Lub, Rianne, Vonk, Steffie E. M., Roukema, Jolt, Reijers, Monique H., Terheggen‐Lagro, Suzanne W. J., Altenburg, Josje, Majoor, Christof J., Bos, Lieuwe D., Haarman, Eric G., Maitland‐van der Zee, Anke H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703582/
https://www.ncbi.nlm.nih.gov/pubmed/36440690
http://dx.doi.org/10.1002/prp2.1015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703582/
https://www.ncbi.nlm.nih.gov/pubmed/36440690
http://dx.doi.org/10.1002/prp2.1015

Ejemplares similares